We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
GSK1904529A, an insulin-like growth factor-1 receptor inhibitor, inhibits glioma tumor growth, induces apoptosis and inhibits migration3.
- Authors
QIANG ZHOU; JUNXIA ZHANG; QINYING CUI; XIAODONG LI; GE GAO; YANFEN WANG; YUPING XU; XIAOQUN GAO
- Abstract
Malignant gliomas are the most common type of primary malignancy of the central nervous system, with a poor prognosis. The therapeutic options for malignant gliomas are limited and far from satisfactory, and novel treatment strategies are urgently required to improve the outcome of the disease. Insulin-like growth factor (IGF)/IGF-1 receptor (IGF-1R) signaling pathway regulates cell proliferation, motility and survival. The dysregulation of this signaling pathway has been implicated in the development of malignant gliomas. In the present study, GSK1904529A, a small molecule inhibitor of IGF-1R, suppressed glioma cell viability, induced glioma cell apoptosis and inhibited glioma cell migration in vitro. In addition, GSK1904529A inhibited glioma tumor growth and induced tumor cell apoptosis in vivo. In conclusion, the results of the present study suggested GSK1904529A as a promising agent for the treatment of malignant glioma.
- Subjects
GLIOMA treatment; INSULIN-like growth factor receptors; SOMATOMEDIN C; APOPTOSIS; CELL migration; TUMOR growth prevention; PHOSPHORYLATION; PREVENTION
- Publication
Molecular Medicine Reports, 2015, Vol 12, Issue 3, p3381
- ISSN
1791-2997
- Publication type
Article
- DOI
10.3892/mmr.2015.3869